On the stock market since 2013, it operates in the world of health and science. It has 293 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $149.5M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 61 buys and 49 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $6.00 — 47% above today’s price.
A loss of $74.6M against $149.5M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 11/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 36/100.
On our five-subject report card, MGNX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MGNX is a small company that closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (36/100) says the stock isn’t cheap.